Clarity Pharmaceuticals bags FDA fast track designation for prostate cancer candidate 67Cu-SAR-bisPSMA
Clarity Pharmaceuticals has achieved a major regulatory milestone with the United States Food and Drug Administration (FDA) granting Fast Track Designation to 67Cu-SAR-bisPSMA, a targeted ... Read More
Prostate cancer diagnosis: A breakthrough in non-invasive testing
Prostate cancer is one of the most prevalent cancers affecting men globally, ranking sixth in occurrence after cancers of the lung, stomach, liver, colon, and ... Read More
Biomerica’s Fortel PSA Test gains approval for prostate cancer detection in UAE
The United Arab Emirates Ministry of Health and Prevention (MOHAP) has granted regulatory approval for the Fortel Prostate Specific Antigen (PSA) Screening Test, a groundbreaking ... Read More
Zydus Lifesciences bags FDA tentative approval for Enzalutamide Tablets for prostate cancer treatment
Zydus Lifesciences Limited has secured tentative approval from the United States Food and Drug Administration (USFDA) for its Enzalutamide Tablets, available in 40 mg and ... Read More
Zydus Lifesciences launches fight against prostate cancer with new FDA-approved drug enzalutamide
Zydus Lifesciences Limited has achieved a significant milestone in the pharmaceutical industry. The company recently received final approval from the United States Food and Drug ... Read More
Merck secures exclusive global license for opevesostat from Orion Corporation
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has enhanced its strategic position in the oncology market by securing an ... Read More
Telix Pharmaceuticals advances prostate cancer treatment with successful TLX592 study
Telix Pharmaceuticals Limited (ASX: TLX) has announced the successful completion of the CUPID Phase I dose escalation study of TLX592, marking a significant advancement in ... Read More
AstraZeneca to acquire Fusion Pharmaceuticals to boost cancer radioconjugate development
In a strategic move to revolutionize cancer treatment, AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a pioneer in the development of ... Read More
Fusion Pharmaceuticals secures rights for advanced prostate cancer treatment from Heidelberg University and Euratom
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a trailblazer in the oncology sector specializing in the development of next-generation radiopharmaceuticals, has announced a landmark exclusive worldwide license ... Read More
Clarity Pharmaceuticals advances in SECuRE trial with promising prostate cancer treatment results
Clarity Pharmaceuticals (ASX: CU6), a clinical stage radiopharmaceutical company, announced significant progress in the SECuRE trial, marking a pivotal step in cancer treatment research. The ... Read More